In addition, the administration of the aforementioned extracellular vesicles to mice under T cell transfer experimental colitis improved colitis severity by a mechanism involving TGF-β, since the use of neutralizing antibodies against this cytokine abolished the therapeutic effects of the extracellular vesicles [110]. Here, TGFB1 is linked to colitis.